The Role of Lipid Accumulation Product (LAP) as a Metabolic Indicator in Polycystic Ovary Syndrome (PCOS)

Abstract

Polycystic ovary syndrome (PCOS) presents one of the most widespread endocrine disorders affecting women of reproductive age, predominantly characterized by hyperandrogenism, anovulation, and polycystic ovaries. Women diagnosed with PCOS also present an increased risk for developing metabolic complications like dyslipidemia, metabolic syndrome (MetS) insulin resistance (IR) and type 2 diabetes mellitus. With effective early detection becoming critical to managing these adverse effects, Lipid Accumulation Product (LAP) has emerged as a reliable marker for detecting excessive lipid accumulation beyond adipose tissue, such as in the liver, often associated with cardiometabolic risk; especially among patients with PCOS. This review examines the link between the application of LAP as a predictor of cardiometabolic risks and its association to PCOS, hence seeking possible implementations in clinical settings towards early diagnosis and improved management for affected individuals.